News
RDY
12.18
+0.58%
0.07
Securities Fraud Investigation Into Dr. Reddy’s Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Barchart · 2d ago
Securities Fraud Investigation Into Dr. Reddy’s Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Barchart · 3d ago
Dr. Reddy’s Receives USFDA Form 483 for Bachupally Plant After August Inspection
TipRanks · 5d ago
Dr. Reddy’s Receives VAI Classification as USFDA Closes Inspection of U.K. API Plant
TipRanks · 5d ago
Weekly Report: what happened at RDY last week (0810-0814)?
Weekly Report · 5d ago
Dr. Reddy’s says FDA inspection of UK facility ‘officially closed’
TipRanks · 6d ago
RDY SHAREHOLDER ALERT: Dr. Reddy’s Laboratories Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Barchart · 08/13 19:00
Dr. Reddy’s Announces Resignation of API and Services CEO Deepak Sapra
TipRanks · 08/13 14:17
Dr. Reddy’s Ends Novartis India Brand Distribution Pact, Plans Transition by September 2026
TipRanks · 08/10 16:48
Weekly Report: what happened at RDY last week (0803-0807)?
Weekly Report · 08/10 10:06
Novartis India Approves Termination Of Distribution Agreement With Dr. Reddy’s Laboratories; Termination Agreement With Dr. Reddy’s Effective September 30, 2026; To Re-Buy Exclusivity And Market Access For Products After DRL Agreement Termination
Benzinga · 08/07 15:36
Dr. Reddy's Launches First-to-Market Generic Sugammadex Injection In The U.S
NASDAQ · 08/04 07:32
Fresenius announces FDA approval of rituximab biosimilar
TipRanks · 08/03 20:15
Dr. Reddy’s Wins U.S. FDA Nod for Rituximab Biosimilar, Deepening Biosimilars Push
TipRanks · 08/03 10:48
Weekly Report: what happened at RDY last week (0727-0731)?
Weekly Report · 08/03 10:05
Low Growth Viatris Is Due For A Pullback After A Stellar 16-Month Run
Seeking Alpha · 07/31 21:15
Dr. Reddy's Laboratories (RDY) Securities Investigation Notice - Levi & Korsinsky
PR Newswire · 07/31 14:07
Dr. Reddy’s Laboratories Announces U.S. FDA Completes Inspection at Srikakulam Unit, Issues Form 483
Benzinga · 07/29 16:30
Weekly Report: what happened at RDY last week (0720-0724)?
Weekly Report · 07/27 10:09
Dr. Reddy's Laboratories Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Dr. Reddy's Laboratories (RDY)
PR Newswire · 07/24 21:06
More
Webull provides a variety of real-time RDY stock news. You can receive the latest news about Dr Reddys Labs through multiple platforms. This information may help you make smarter investment decisions.
About RDY
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.